Definition and research guide
This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.
Content available: 3 complete abstracts (617 words), 9 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.
Definition
An epithelium with mucus-secreting cells, such as goblet cells. It forms the lining of many body cavities, such as the digestive tract, the respiratory tract, and the reproductive tract. Mucosa, rich in blood and lymph vessels, comprises an inner epithelium, a middle layer (lamina propria) of loose connective tissue, and an outer layer (muscularis mucosae) of smooth muscle cells that separates the mucosa from submucosa.
Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.
Also known as: Membrane, Mucous; Membranes, Mucous; Mucosa; Mucosal Tissue; Mucosal Tissues; Tissue, Mucosal; Tissues, Mucosal; Mucous Membranes.
Where it fits in the MeSH classification
- Broader topics
- Membranes
- Narrower topics
- Esophageal Mucosa; Gastric Mucosa; Hymen; Intestinal Mucosa; M Cells; Mouth Mucosa; Respiratory Mucosa
- See also
- Administration, Mucosal
Related concepts
Research landscape
PubMed indexes 249,900 records tagged with the MeSH heading “Mucous Membrane” (counts retrieved 2026-10-31). 29,959 of them (12.0%) were published from 2020 onward, and the busiest period so far is through 1999 with 107,582 records.
Reviews account for 24,607 records (9.8%) and meta-analyses for 487. Randomized controlled trials number 4,284 (1.7%) as a share of all records on the topic. Randomized trials make up only a small share of this literature, so much of what is known comes from laboratory, observational or descriptive work.
Show the data
| Period | Records |
|---|---|
| through 1999 | 107,582 |
| 2000-2009 | 52,086 |
| 2010-2019 | 60,273 |
| 2020 onward | 29,959 |
Publication-type chart data
| Type | Records | Share |
|---|---|---|
| Reviews | 24,607 | 9.8% |
| Meta-analyses | 487 | 0.2% |
| Randomized controlled trials | 4,284 | 1.7% |
Method: PubMed query "Mucous Membrane"[MeSH Terms] with publication-type and date filters, retrieved 2026-10-31.
Reading the evidence in anatomy and physiology
Anatomy describes how body structures are built and physiology describes how they normally work, so most findings here are descriptive or mechanistic rather than evidence about treatment. Much of what is known comes from dissection, imaging, tissue studies and experiments in animals, and measurements in healthy volunteers can differ from those in people with disease or at different ages. Normal ranges vary between individuals and populations. Check whether a result was measured in people or in another species, the age and health of the participants, and the method used.
Evidence from open-access studies
These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.
| Study / authors | Year | Source label / design | Europe PMC citations | Licence / source |
|---|---|---|---|---|
| Urolithin A activates aryl hydrocarbon receptor-NLRP6-mediated pathways in intestinal epithelial cells to modulate mucosal immunity and strengthen gut barrier integrity | 2026 | Research article Design not recorded in structured metadata | 4 | cc by PMID 42336837 · DOI · PMC13291259 |
| Context-Dependent Epithelial and Immune Programs Shape Intestinal Resilience or Vulnerability Following Prior Colitis | 2026 | Research article Design not recorded in structured metadata | 2 | cc by PMID 42269772 · DOI · PMC13400666 |
| The airway epithelial-immune axis: mechanisms and therapeutic implications | 2026 | Review article Design not recorded in structured metadata | 2 | cc by PMID 42568577 · DOI · PMC13447427 |
Urolithin A activates aryl hydrocarbon receptor-NLRP6-mediated pathways in intestinal epithelial cells to modulate mucosal immunity and strengthen gut barrier integrity [1]
Abstract reading summary — source excerpts
- Opening excerpt
- The aryl hydrocarbon receptor (AHR) plays a central role in orchestrating gut barrier and mucosal immune functions in the pathogenesis of inflammatory bowel disease (IBD).
- Closing excerpt
- These results demonstrate that activation of AHR by UroA modulates intestinal barrier function through an NLRP6-IL-18-IL-22 pathway in both healthy and IBD conditions.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (157 words)
The aryl hydrocarbon receptor (AHR) plays a central role in orchestrating gut barrier and mucosal immune functions in the pathogenesis of inflammatory bowel disease (IBD). Nevertheless, activation of the AHR by diverse ligands yields varied outcomes, and the downstream pathways responsible for these effects remain unknown. Here, we report that selective activation of AHR in mouse intestinal epithelial cells (IEC) by the microbial metabolite, urolithin A (UroA), triggers the Nod-like receptor pyrin domain-containing protein 6 (NLRP6) inflammasome, resulting in the release of interleukin (IL)-18 but not IL-1β. Further, we show that UroA-induced IL-18 in IECs is critical for IL-22, mucin 2 and REG3γ production, as well as protection against colitis. Moreover, UroA significantly upregulates IL-18 and IL-22 levels in IECs and type-3 innate lymphoid cells, respectively, in intestinal biopsies from patients with IBD patients. These results demonstrate that activation of AHR by UroA modulates intestinal barrier function through an NLRP6-IL-18-IL-22 pathway in both healthy and IBD conditions.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 42336837 · DOI · PMC13291259
Context-Dependent Epithelial and Immune Programs Shape Intestinal Resilience or Vulnerability Following Prior Colitis [2]
Abstract reading summary — source excerpts
- Opening excerpt
- Background & aimsPrior intestinal inflammation can leave durable immune and epithelial alterations, yet how these changes influence responses to subsequent injury remains unclear.
- Closing excerpt
- These findings highlight how inflammatory history influences long-term intestinal resilience or vulnerability.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (280 words)
Background & aimsPrior intestinal inflammation can leave durable immune and epithelial alterations, yet how these changes influence responses to subsequent injury remains unclear. Infectious and sterile colitis share core features, including barrier disruption and cytokine secretion. We therefore investigated whether the nature of the initial inflammatory event shapes protection or susceptibility during later intestinal insult.MethodsWe used reciprocal mouse models of Citrobacter rodentium infection and dextran sodium sulphate-induced colitis to define how prior infectious vs sterile colitis shapes secondary disease. Barrier integrity, immune cell populations, cytokine production, and susceptibility to wild-type and C rodentium mutants that cause limited epithelial barrier disruption were assessed.ResultsMice recovered from C rodentium infection were protected against dextran sodium sulphate-induced colitis, displaying reduced weight loss, preserved epithelial architecture, and lower inflammatory pathology. This protection required type III secretion system effector-mediated epithelial injury during primary infection and was associated with sustained interleukin17A signaling, which contributed to the protective phenotype. In contrast, mice recovered from dextran sodium sulphate-induced colitis exhibited persistent epithelial barrier defects, chronic colonic neutrophilia, and heightened susceptibility to C rodentium infection despite elevated interleukin17A. Infection with C rodentium mutants that cause minimal epithelial damage still resulted in severe disease in dextran sodium sulphate-experienced mice, indicating that unresolved epithelial barrier dysfunction is a major contributor to vulnerability.ConclusionsThe nature of the primary colitis is associated with distinct epithelial and immune programs that persist beyond resolution of inflammation. Infectious colitis is associated with a protective mucosal state where interleukin17A is a key contributor in a broader protective response, whereas sterile colitis is associated with persistent epithelial barrier dysfunction that is associated with increased susceptibility to subsequent infection. These findings highlight how inflammatory history influences long-term intestinal resilience or vulnerability.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 42269772 · DOI · PMC13400666
The airway epithelial-immune axis: mechanisms and therapeutic implications [3]
Abstract reading summary — source excerpts
- Opening excerpt
- The airway epithelium is increasingly recognized not merely as a physical barrier, but as a central, active regulator of mucosal immunity.
- Closing excerpt
- Furthermore, we highlight how emerging technologies-such as single-cell RNA sequencing, spatial transcriptomics, organoid models, and multi-omics integration-are decoding cellular heterogeneity and spatial niches, ultimately paving the way for precision medicine and long-term disease-modifying therapies in respiratory medicine.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (180 words)
The airway epithelium is increasingly recognized not merely as a physical barrier, but as a central, active regulator of mucosal immunity. This review comprehensively summarizes the structural and functional basis of the airway epithelial-immune axis and its critical role in chronic respiratory diseases. Exposure to environmental allergens, pollutants, and respiratory pathogens disrupts epithelial tight junctions and triggers the rapid release of key alarmins, including TSLP, IL-33, and IL-25. These epithelial-derived cytokines participate in reciprocal epithelial-immune circuits, driving extensive crosstalk with both innate (ILC2s) and adaptive (Th2 cells) immune networks to establish self-perpetuating inflammatory loops. Such epithelial dysfunction can act as an important driver and amplifier in the pathogenesis of asthma, chronic obstructive pulmonary disease (COPD), and upper airway inflammatory disorders. Consequently, targeting this axis has emerged as a promising therapeutic strategy, shifting the focus toward alarmin-neutralizing biologics, upstream receptor inhibition, and barrier restoration. Furthermore, we highlight how emerging technologies-such as single-cell RNA sequencing, spatial transcriptomics, organoid models, and multi-omics integration-are decoding cellular heterogeneity and spatial niches, ultimately paving the way for precision medicine and long-term disease-modifying therapies in respiratory medicine.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 42568577 · DOI · PMC13447427
Key reviews and meta-analyses
The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.
- Research article Mucosal Healing Is Associated With Improved Long-term Outcomes of Patients With Ulcerative Colitis: A Systematic Review and Meta-analysis [4]
- Research article Systematic review with meta-analysis: mucosal healing is associated with improved long-term outcomes in Crohn's disease [5]
- Research article Meta-analysis of endoscopic submucosal dissection versus endoscopic mucosal resection for tumors of the gastrointestinal tract [6]
- Research article Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials [7]
- Research article A meta-analysis of endoscopic submucosal dissection and EMR for early gastric cancer [8]
- Research article A systematic review of the prevalence of mucosal and cutaneous human papillomavirus types [9]
References
- Ghosh S, Vanwinkle ZM, Bodduluri SR, Juin SK, Kadari M, Singh A, et al.. Urolithin A activates aryl hydrocarbon receptor-NLRP6-mediated pathways in intestinal epithelial cells to modulate mucosal immunity and strengthen gut barrier integrity. . 2026. PMID 42336837 · DOI · PMC13291259
- Biswas P, Mishra V, Sanchez-Garrido J, Frankel G. Context-Dependent Epithelial and Immune Programs Shape Intestinal Resilience or Vulnerability Following Prior Colitis. . 2026. PMID 42269772 · DOI · PMC13400666
- Zhu Z, Li Q, Hua B. The airway epithelial-immune axis: mechanisms and therapeutic implications. . 2026. PMID 42568577 · DOI · PMC13447427
- Shah SC, Colombel JF, Sands BE, Narula N. Mucosal Healing Is Associated With Improved Long-term Outcomes of Patients With Ulcerative Colitis: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2016. PMID 26829025 · DOI
- Shah SC, Colombel JF, Sands BE, Narula N. Systematic review with meta-analysis: mucosal healing is associated with improved long-term outcomes in Crohn's disease. Aliment Pharmacol Ther. 2016. PMID 26607562 · DOI
- Cao Y, Liao C, Tan A, Gao Y, Mo Z, Gao F. Meta-analysis of endoscopic submucosal dissection versus endoscopic mucosal resection for tumors of the gastrointestinal tract. Endoscopy. 2009. PMID 19693750 · DOI
- Cholapranee A, Hazlewood GS, Kaplan GG, Peyrin-Biroulet L, Ananthakrishnan AN. Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials. Aliment Pharmacol Ther. 2017. PMID 28326566 · DOI · PMC5395316
- Lian J, Chen S, Zhang Y, Qiu F. A meta-analysis of endoscopic submucosal dissection and EMR for early gastric cancer. Gastrointest Endosc. 2012. PMID 22884100 · DOI
- Bzhalava D, Guan P, Franceschi S, Dillner J, Clifford G. A systematic review of the prevalence of mucosal and cutaneous human papillomavirus types. Virology. 2013. PMID 23928291 · DOI
About this article
- Sources
- NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
- Verification
- Every reference was resolved against PubMed on 2026-10-31; title, year and DOI matched.
- Review state
- automated source verified; no human expert review has been recorded yet.
- Version
- 1, last updated 2026-10-31.
See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.
Evidence strength
EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.